25
Apr
2015
FDA approves first generic Copaxone to treat multiple sclerosis
The U.S. Food and Drug Administration today approved the first generic version of Copaxone (glatiramer acetate injection), used to treat patients with relapsing forms of multiple sclerosis (MS).
Sandoz has received FDA approval to market generic glatiramer acetate in a 20 mg/1 ml daily injection.
Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone – as marketed by Teva Pharmaceuticals) is an immunomodulator drug currently used to treat multiple sclerosis.
Glatiramer acetate has been approved for marketing in 49 countries worldwide, including the United States, Israel, Canada and 24 European Union Countries.